Insider trading

Period: 120 months Stock: CBIO Role: Other officers × + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

30 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

30 decisions over 120 months Remove this filter
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

30 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

30 decisions over 120 months
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
30 decisions over 120 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
30 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

30 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
18 Sep 2026
McNeill Jonathan President and COO
Sold on a plan
$64.15K 3,839 at 16.71
2.8%
Planned (10b5-1)
16 Sep 2026
McNeill Jonathan President and COO
Sold on a plan
$13.08K 731 at 17.90
0.5%
Planned (10b5-1)
16 Sep 2026
Pinkas Jan Chief Scientific Officer
Sold on a plan
$11.78K 658 at 17.90
3.0%
Planned (10b5-1)
16 Sep 2026
Im Ellie Eunkyung Chief Medical Officer
Sold on a plan
$11.15K 623 at 17.90
2.8%
Planned (10b5-1)
16 Sep 2026
Sold on a plan
$11.10K 620 at 17.90
3.2%
Planned (10b5-1)
16 Sep 2026
Lynch Ryan See Remarks
Sold on a plan
$4.30K 240 at 17.90
1.7%
Planned (10b5-1)
22 Jun 2026
McNeill Jonathan President and COO
Sold on a plan
$369.68K 20,549 at 17.99
12.9%
Planned (10b5-1)
22 Jun 2026
Pinkas Jan Chief Scientific Officer
Sold on a plan
$23.17K 1,288 at 17.99
5.5%
Planned (10b5-1)
22 Jun 2026
Im Ellie Eunkyung Chief Medical Officer
Sold on a plan
$21.93K 1,219 at 17.99
5.2%
Planned (10b5-1)
22 Jun 2026
Sold on a plan
$21.91K 1,218 at 17.99
5.9%
Planned (10b5-1)
22 Jun 2026
Lynch Ryan See Remarks
Sold on a plan
$8.37K 465 at 17.99
3.2%
Planned (10b5-1)
21 Jun 2024
Rock Edwin Chief Medical Officer
Bought
$30.72K 115,000 at 0.27
20.3%
+20% of stake
20 Jun 2024
Rock Edwin Chief Medical Officer
Bought
$48.11K 190,000 at 0.25
50.6%
+51% of stake
22 Sep 2023
Rock Edwin Chief Medical Officer
Bought
$41.96K 30,403 at 1.38
8.8%
21 Sep 2023
Rock Edwin Chief Medical Officer
Bought
$48.30K 35,000 at 1.38
11.3%
8 May 2023
Johnson Bruce S SVP & Chief Commercial Officer
Bought
$21.20K 13,500 at 1.57
10.8%
First buy on file
22 Dec 2022
Rock Edwin Chief Medical Officer
Bought
$247.50K 110,000 at 2.25
55.0%
Largest buy in 3 yrs
15 Nov 2022
Rock Edwin Chief Medical Officer
Bought
$166.00K 100,000 at 1.66
100%
Largest buy in 3 yrs
14 Nov 2022
Rock Edwin Chief Medical Officer
Bought
$143.00K 100,000 at 1.43
opened
First buy on file
11 Nov 2022
Magnani John L. SVP of Research, CSO
Bought
$52.70K 45,045 at 1.17
14.0%
First buy on file
11 Nov 2022
Girard Armand SVP, Chief Business Officer
Bought
$6.83K 6,500 at 1.05
28.7%
First buy on file
9 Mar 2022
Magnani John L. SVP of Research, CSO
Sold, plan not stated
$3.52K 3,227 at 1.09
1.0%
9 Mar 2022
Girard Armand SVP, Chief Business Officer
Sold, plan not stated
$2.55K 2,339 at 1.09
9.4%
18 Oct 2018
Magnani John L. SVP of Research, CSO
Sold, plan not stated
$49.45K 3,527 at 14.02
4.4%
17 Oct 2018
Magnani John L. SVP of Research, CSO
Sold, plan not stated
$101.82K 7,273 at 14.00
8.4%
16 Oct 2018
Magnani John L. SVP of Research, CSO
Sold, plan not stated
$198.94K 14,200 at 14.01
14.1%
8 Dec 2017
Thackray Helen M. SVP Clinical Development, CMO
Sold, plan not stated
$30.02K 2,000 at 15.01
1.3%
18 Sep 2017
Thackray Helen M. SVP Clinical Development, CMO
Sold, plan not stated
$26.00K 2,000 at 13.00
1.3%
25 May 2017
Thackray Helen M. SVP Clinical Development, CMO
Sold, plan not stated
$31.14K 2,000 at 15.57
1.3%
19 May 2017
Thackray Helen M. SVP Clinical Development, CMO
Sold, plan not stated
$24.28K 2,000 at 12.14
1.3%
Showing 1–30 of 30.